ADI-PEG20, a pharmacological Arg-degrading agent that depletes extracellular Arg by converting it to Cit, has been investigated in pre-clinical studies and shown promise in clinical trials for cancers with low ASS1 expression, including melanoma and hepatocellular carcinoma 11. Here, ASS1 is linked to hepatocellular carcinoma.